HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China

HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces an update regarding TAZVERIK® (tazemetostat), an oncology therapy licensed from …

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (HUTCHMED or the Company) (Nasdaq/AIM:HCM; HKEX:13) today announces an update regarding TAZV… [+8068 chars]